StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$165.31−2.09 (-1.25%)

Close on Nov 16, 2026Market cap $16.80BP/E 24.5Yield –

Neurocrine Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Neurocrine Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.23B, up 30.7% year over year. For fiscal 2025 it was $1.02B, up 38.9% from the year before. Over ten years it grew 36.1% a year on average. The highest annual figure on record is $1.02B in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.02B+38.9%
FY2024Dec 31, 2024$731.10M+29.4%
FY2023Dec 31, 2023$565.00M+21.8%
FY2022Dec 31, 2022$463.80M+41.4%
FY2021Dec 31, 2021$328.10M+19.3%
FY2020Dec 31, 2020$275.00M+71.3%
FY2018Dec 31, 2018$160.52M+31.8%
FY2017Dec 31, 2017$121.83M+29.2%
FY2016Dec 31, 2016$94.29M+15.7%
FY2015Dec 31, 2015$81.49M+75.5%
FY2014Dec 31, 2014$46.43M+18.3%
FY2013Dec 31, 2013$39.25M+5.6%
FY2012Dec 31, 2012$37.16M+20.1%
FY2011Dec 31, 2011$30.95M-0.6%
FY2010Dec 31, 2010$31.15M-7.6%
FY2009Dec 31, 2009$33.72M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$351.80M+40.7%
Q2 FY2026Jun 30, 2026$326.70M+33.7%
Q1 FY2026Mar 31, 2026$296.20M+12.5%
Q4 FY2025Dec 31, 2025$258.20M+39.1%
Q3 FY2025Sep 30, 2025$250.00M+28.2%
Q2 FY2025Jun 30, 2025$244.30M+27.8%
Q1 FY2025Mar 31, 2025$263.20M+65.1%
Q4 FY2024Dec 31, 2024$185.60M+35.0%
Q3 FY2024Sep 30, 2024$195.00M+37.1%
Q2 FY2024Jun 30, 2024$191.10M+31.1%
Q1 FY2024Mar 31, 2024$159.40M+14.3%
Q4 FY2023Dec 31, 2023$137.50M+16.5%
Q3 FY2023Sep 30, 2023$142.20M+32.0%
Q2 FY2023Jun 30, 2023$145.80M+7.3%
Q1 FY2023Mar 31, 2023$139.50M+36.5%
Q4 FY2022Dec 31, 2022$118.00M+35.0%
Q3 FY2022Sep 30, 2022$107.70M+16.2%
Q2 FY2022Jun 30, 2022$135.90M+81.7%
Q1 FY2022Mar 31, 2022$102.20M+39.6%
Q4 FY2021Dec 31, 2021$87.40M+31.0%
Q3 FY2021Sep 30, 2021$92.70M+34.2%
Q2 FY2021Jun 30, 2021$74.80M-7.5%
Q1 FY2021Mar 31, 2021$73.20M+25.6%
Q4 FY2020Dec 31, 2020$66.70M+47.2%
Q3 FY2020Sep 30, 2020$69.10M+12.0%
Q2 FY2020Jun 30, 2020$80.90M+114.9%
Q1 FY2020Mar 31, 2020$58.30M+49.1%
Q3 FY2019Sep 30, 2019$45.30M+27.7%
Q2 FY2019Jun 30, 2019$61.70M+66.8%
Q1 FY2019Mar 31, 2019$37.65M-23.1%
Q4 FY2018Dec 31, 2018$39.11M+52.7%
Q3 FY2018Sep 30, 2018$35.48M+58.0%
Q2 FY2018Jun 30, 2018$36.99M+69.1%
Q1 FY2018Mar 31, 2018$48.95M-5.7%
Q4 FY2017Dec 31, 2017$25.61M+13.4%
Q3 FY2017Sep 30, 2017$22.46M–
Q2 FY2017Jun 30, 2017$21.87M–
Q1 FY2017Mar 31, 2017$51.88M–
Q4 FY2016Dec 31, 2016$22.58M–

More Neurocrine Biosciences figures

See a number that looks wrong?